A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Gemcitabine (Primary) ; Sirolimus (Primary)
- Indications Leiomyosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
Most Recent Events
- 16 Aug 2024 Status changed from not yet recruiting to recruiting.
- 18 Mar 2024 New trial record